Tibor S. and colleagues conducted a clinical study analyzing serum samples from 82 bladder cancer patients, comparing them with 20 healthy patients, with the aim of better understanding bFGF in bladder cancer and assessing the prognostic significance of their serum levels [170]. This evidence concerns the gene FGF2 and urinary bladder carcinoma.